Angelopoulos Nikolaos, Goulis Dimitrios G, Chrisogonidis Ioannis, Livadas Sarantis, Paparodis Rodis, Androulakis Ioannis, Iakovou Ioannis
2(nd) Academic Department of Nuclear Medicine, AHEPA University Hospital, Faculty of Medicine, School of Health Sciences, Thessaloniki, Greece; Hellenic Endocrine Network, Ermou 6, Athens, Greece.
Unit of Reproductive Endocrinology, 1(st) Department of Obstetrics and Gynecology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Endocr Pract. 2025 Jan;31(1):72-79. doi: 10.1016/j.eprac.2024.10.004. Epub 2024 Oct 22.
The challenge of selecting thyroid nodules for fine needle aspiration (FNA) cytology has led to the development of the Thyroid Imaging Reporting and Data System, primarily in 2 formats: European Thyroid Imaging Reporting and Data System (EU-TIRADS) and American College of Radiology Thyroid Imaging Reporting and Data System (ACR-TIRADS). Clinical observations suggest imperfect risk assessment for TIRADS 3 nodules ≥20 mm. This study aimed to evaluate the efficacy of TIRADS systems in distinguishing benign from malignant nodules in this subgroup.
From May 2023 to March 2024, 1094 patients with thyroid nodules were referred for ultrasound at a University Hospital. Data on clinical, ultrasound, cytological, and histopathological parameters were collected. Nodules ≥20 mm were categorized by EU-TIRADS and ACR-TIRADS, and their predictive performance for malignancy was assessed through postthyroidectomy histopathology or FNA cytology (Bethesda classification).
Two hundred sixty-seven patients (mean age 60.3 ± 14.3 years; 46 men, 221 women) with 308 nodules were analyzed. Twenty-two malignancies and 286 benign nodules were recorded. Recalculating European Thyroid Imaging Reporting and Data System 3 performance using 25-mm and 30-mm thresholds (ACR-modified EU-TIRADS) avoided 24% and 41% of FNAs, respectively, while ACR-TIRADS would prevent 26.6% (P > .05). Two malignancies were missed.
EU-TIRADS and ACR-TIRADS show similar efficacy when using a 25 mm FNA threshold. Raising the cutoff for FNA in European Thyroid Imaging Reporting and Data System 3 nodules could reduce unnecessary procedures but may increase the risk of missed malignancies, impacting patient outcomes.
选择甲状腺结节进行细针穿刺(FNA)细胞学检查面临挑战,这促使了甲状腺影像报告和数据系统的发展,主要有两种形式:欧洲甲状腺影像报告和数据系统(EU-TIRADS)以及美国放射学会甲状腺影像报告和数据系统(ACR-TIRADS)。临床观察表明,对于直径≥20 mm的TIRADS 3类结节,风险评估并不完善。本研究旨在评估TIRADS系统在区分该亚组中良性和恶性结节方面的有效性。
2023年5月至2024年3月,1094例甲状腺结节患者在一家大学医院接受超声检查。收集了临床、超声、细胞学和组织病理学参数的数据。直径≥20 mm的结节按照EU-TIRADS和ACR-TIRADS进行分类,并通过甲状腺切除术后组织病理学或FNA细胞学检查(贝塞斯达分类)评估其对恶性肿瘤的预测性能。
分析了267例患者(平均年龄60.3±14.3岁;男性46例,女性221例)的308个结节。记录到22例恶性肿瘤和286例良性结节。使用25 mm和30 mm阈值重新计算欧洲甲状腺影像报告和数据系统3的性能(ACR改良的EU-TIRADS)分别避免了24%和41%的FNA检查,而ACR-TIRADS可避免26.6%(P>.05)。漏诊了2例恶性肿瘤。
当使用25 mm FNA阈值时,EU-TIRADS和ACR-TIRADS显示出相似的有效性。提高欧洲甲状腺影像报告和数据系统3类结节的FNA临界值可减少不必要的检查,但可能增加漏诊恶性肿瘤的风险,从而影响患者的治疗结果。